NexImmune to Present at the Barclays 2022 Global Healthcare Conference
NexImmune, a clinical-stage biotechnology company, will have its CEO, Kristi Jones, present at the Barclays 2022 Global Healthcare Conference on March 17, 2022, at 8:30 a.m. ET. The presentation will provide insights into the company's innovative immunotherapy approach that utilizes proprietary AIM nanoparticle technology to target T cells for a robust immune response. NexImmune's lead programs, NEXI-001 and NEXI-002, are in clinical trials for treating relapsed AML post-stem cell transplantation and refractory multiple myeloma. A replay will be available for 30 days post-conference.
- None.
- None.
GAITHERSBURG, Md., March 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones, Chief Executive Officer, will present at the Barclays 2022 Global Healthcare Conference on Thursday, March 17, 2022 at 8:30 a.m. Eastern Time.
The webcast will be accessible on the Investor Relations page of NexImmune’s website at Events and Presentations | NexImmune, Inc. A replay of the presentation will be available at the same location for 30 days following the conference.
About NexImmune
NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.
NexImmune’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to 3 or more prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.
For more information, visit www.neximmune.com.
Contacts
Investors:
Chad Rubin, SVP Corporate Affairs
NexImmune, Inc.
crubin@neximmune.com
FAQ
What is NexImmune's stock symbol?
When will NexImmune present at the Barclays 2022 Global Healthcare Conference?
What is the focus of NexImmune's immunotherapy approach?
What are the lead programs currently in trial by NexImmune?
Where can I watch the NexImmune conference presentation?
